Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) ...
Sep 24, 2018
0
1